FDA to accelerate review of Wyeth infant vaccine

05/8/2009 | Forbes

The FDA granted priority-review status to Wyeth's infant vaccine Prevnar 13. The drug protects against seven strains of Streptococcus pneumoniae bacteria already included in the original Prevnar formulation, plus six other strains that cause similar infectious diseases.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN